Abstract. One of the most important prognostic factors in the thrombolytic treatment of acute ischemic stroke is to recanalize. The purpose of this study was to evaluate the effectiveness and safety of urokinase in a primate thromboembolic stroke model. Thromboembolic stroke was accomplished via occlusion of the middle cerebral artery (MCA) obtained by injecting an autologous blood clot into the left internal carotid artery in 21 male cynomolgus monkeys. Animals were randomly assigned to the following treatment groups: Group 1: vehicle (saline), Group 2: urokinase (40,000 IU), Group 3: urokinase (120,000 IU,) over 2 or 6 h via intra-internal carotid catheter starting 1 h after embolization, respectively. In the urokinase-treated groups, neurologic deficits were improved in consciousness and skeletal muscle coordination, but not sensory and motor systems. The infarction size in Group 2 (11.9 ± 3.9% of the hemisphere) and 3 (7.6 ± 2.5%) were significantly smaller than that (24.7 ± 3.5%) in Group 1. However, 2 of 5 animals in Group 3 died. In conclusion, urokinase improved neurologic deficits and reduced cerebral infarction on thromboembolic stroke in the cynomolgus monkey.
Introduction
Intra-arterial cerebral fibrinolytic therapy using streptokinase through the vertebrobasilar artery for acute embolic stroke was originally performed in 1983 by Zeumer et al. (1) . Multiple clinical reports have supported that intra-arterial thrombolytic therapy may be useful for treatment of acute ischemic stroke (2 -8) . Because most cases of ischemic stroke are due to thromboembolic occlusion of an artery supplying blood to the brain (9, 10) , the blood supply into the brain is the most important factor for the treatment of patients with ischemic stroke. Therefore, thrombolytic therapy is feasible for patients with acute ischemic stroke. Occlusion of a brain vessel leads to a critical reduction in cerebral perfusion and, within minutes, to ischemic infarction, with a central infarct core of irreversibly damaged brain tissue. Therefore, the underlying rationale for the introduction and application of thrombolytic agents is the lysis of a thrombus and the subsequent reestablishment of cerebral blood flow by cerebrovascular recanalization (11, 12) .
In 1996, the FDA approved the use of recombinant tissue plasminogen activator (rt-PA) for treatment of patients within the first 3 h of ischemic stroke. Intravenous rt-PA is the first and currently the only drug approved by the FDA for the treatment of acute stroke. However, thrombolytic administration significantly increases the risk of cerebral hemorrhage. At present, thrombolytic therapy is still underutilized. In Japan, urokinase was approved for the treatment of acute stroke in 1985, but the feasibility as a neuroprotective drug for acute stroke is currently under investigation.
In many animal models described, thromboembolic stroke and reversible cerebral ischemia have been produced in animals phylogenetically different from humans (13 -20) . An experimental animal model of thrombotic stroke should represent the human vascular anatomy. Recently, a new animal model of swine for evaluation of intravascular thrombolysis was reported, in which the autologous blood clot was injected into the ascending pharyngeal artery and the occluded arteries were observed by serial angiography (21) . We have already reported a model of thromboembolic stroke in conscious cynomolgus monkeys using an autologous blood clot, which parallels the clinical thromboembolic stroke in humans (22) . The purpose of this study was to evaluate the safety and efficacy of intra-arterial thrombolysis using urokinase in monkeys with acute thromboembolic stroke.
Materials and Methods

Animal preparation and procedure
The experiments were carried out on 21 male cynomolgus monkeys weighing 4 -6 kg, 5 to 7 years of age (Source: China, Breeding: Guangxi Primate Center of China, Guangxi, China). All procedures involving animals were approved by the animal care and use committee of Shin Nippon Biomedical Laboratories and were performed in accordance with standards published by the National Research Council (Guide for the Care and Use of Laboratory Animals, NIH OACU), the National Institutes of Health Policy on Human Care and Use of Laboratory Animals. In accordance with these standards, every effort was made to ensure that the subjects were free of pain and discomfort. The principal investigator and the primate handling staff were present for all procedures. The monkeys were housed in cages 68-cm-wide by 62-cm-high by 77-cm-deep (conforming to USDA standards) in a ventilated animal room with controlled temperature (26 ± 3°C), relative humidity (55 ± 15%), and 12 h of light (8:00 to 20:00).
Our procedure to produce the thromboembolic stroke model has been described in detail elsewhere (22) . Briefly, under pentobarbital anesthesia (10 mg / kg, i.v.; Tokyo Kasei Kogyo Co., Ltd., Tokyo) after premedication with xylazine (2 mg / kg, i.m.; Bayer Ltd., Tokyo), a catheter (PE-90; Becton Dickinson and Company, Franklin Lakes, NJ, USA) was implanted into the left internal carotid artery. The catheter was filled with 500 IU/ mL heparin saline solutions and passed subcutaneously to protrude in the dorsal neck. All animals received antibiotics (Mycillinsol sol.; Meiji Seika Kaisha, Ltd., Tokyo) and were allowed to recover for 2 days before embolization.
Embolization Procedure: Three hours before embolization, blood was drawn from the femoral vein into a polyethylene catheter (PE-240, Becton Dickinson and Company) and kept at 37°C for 3 h to allow clot formation. A 10-cm-long piece of the clot was flushed into the internal carotid artery with 1 mL saline, under inhalation anesthesia (sevoflurane; Maruishi Pharmaceutical Co., Ltd., Osaka).
Neurologic evaluation
To assess neurologic deficits, a well-standardized score (22) was assigned 1, 2, 4, 6, and 24 h after embolization. Of the 100 points possible, 28 are assigned to consciousness, 22 to the sensory system, 32 to the motor system, and 18 to skeletal muscle coordination. In a normal animal, the score of each category is 0 points. A blinded observer with experience in evaluating neurologic deficits performed the assessment. Behavior of monkeys was continuously recorded for 24 h with a video recorder.
Histopathological examination
After 24 h of embolization, animals were sacrificed under pentobarbital anesthesia after the last neurologic scoring. The brain was then perfused with cold saline and cut into 4-mm-thick coronal sections. Brain slices were completely immersed in 1% 2,3,5-triphenyltetrazolium chloride (23, 24) (TTC; Wako Pure Chemical Industries, Ltd., Osaka) solution and were incubated at 37°C for 40 min. The left hemispherical area and infarct area in each slice was measured from the photograph using a computerized image analytic system (IPAP; Sumisho Computer System Corporation, Tokyo). The infarct size in each slice was expressed as a percentage of the total left hemispherical area in that slice. The infarct size from all 14 slices was summed and represented as a percentage of the total area of all slices.
Urokinase administration
Experimental protocols are shown in Fig. 1 . The monkeys were assigned to 3 groups. Group 1 served as a control and was treated with saline at a rate of Fig. 1 . Experimental protocol. Group 1: Control; saline was infused for 2 h. Group 2: Urokinase was infused for 2 h (40,000 IU). Group 3: Urokinase was infused for 6 h (120,000 IU). Administration was started 1 h after embolization. Neurologic deficits were observed 1, 2, 4, 6, and 24 h after embolization. (Arrows: observational points). 0.5 mL / kg per hour for 2 h. Group 2 received urokinase at a rate of 20,000 IU / h for 2 h (total dose: 40,000 IU). Group 3 received urokinase at a rate of 20,000 IU / h for 6 h (total dose: 120,000 IU). Saline and urokinase were administered as a continuous intra-arterial infusion into the internal carotid artery starting 1 h following embolization.
Urokinase (Urokinase 120,000 IU/ Vial; Yoshitomi Pharmaceutical Industries, Ltd., Osaka) was given to monkeys through the internal carotid catheter using a tetherless infusion pump (Pegasus ® , Model LAS; Logo Med, Windhagen, Germany). Urokinase was dissolved in 10 mL saline (12,000 IU / mL).
Statistical method
The neurologic deficit score was indicated as Maximum, Median, and Minimum and at the 25th and 75th percentiles; and it was compared with the nonparametric Fig. 2 . Change in total neurologic deficit score after embolization. Group 1: Control, Group 2: Urokinase (40,000 IU), Group 3: Urokinase (120,000 IU). Group 3 consisted of five animals, but two of the five animals died within 4 h following the end of urokinase infusion (from 7 to 11 h after embolization). The lower, middle, and upper horizontal lines of each box represent the 25th, median, and 75th percentiles, respectively. *P<0.05, **P<0.01 vs control group, non-parametric Dunnett's multiple test.
Dunnett's test at the 5% significance level. Infarct size was indicated as the mean ± S.E.M. and was compared with Dunnett's test at the 5% significance level.
Results
Clinical outcome and histopathology in Group 1 as control group
Neurologic deficits after embolization are shown in Fig. 2 . The total neurologic deficit score is the sum of four category scores (Table 1) . Conscious but clouded and accepting were commonly observed in 5 of 10 animals in the consciousness category of neurologic deficits (Score: 8), and drowsiness and aroused with stimulation in other animals were also observed (Score: 10). These neurologic deficits were noted at 6 h and lasted until 24 h after MCA embolization; the neurologic deficit score was slightly improved in only 1 animal. In the sensory system category, contralateral facial sensation, and pinna and pain reflexes to touch or toe pinch completely disappeared in all animals. Absence in contralateral sensory persisted over the following 24 h (data not shown). In the motor system category, severe paralysis of the contralateral hand and leg was observed in all animals. Contralateral upper and lower limbs were also completely flaccid, and this paralysis lasted over the following 24 h (data not shown). In the skeletal muscle coordination category, as shown in Fig. 2 , all animals frequently repeated sitting, and lateral or dorsal recumbence until 24 h after MCA embolization. When posed standing, animals fell without any movement. When walked, animals walked with severe paralysis of the right leg and reduction of right lower limb tone, always resulting in ipsilateral circling.
The infarct area included the caudate, globus pallidus, putamen, and genu of the internal capsule, lustrum, insular cortex, and area around the sulcus lateralis (Fig. 3) .
Effect of urokinase
The total neurologic deficit score of Group 2 (n = 6) significantly improved 2, 4, 6, and 24 h after embolization, and those of Group 3 (n = 3 -5) also significantly improved 6 and 24 h after embolization, when compared to Group 1 (Fig. 2) . In Group 2, the consciousness score tended to improve from 2 to 6 h, and showed significant amelioration 24 h after embolization (P<0.05). In Group 3, the score showed greater amelioration and was significantly improved 2, 4, and 6 h, but not 24 h after embolization. Sensory and motor systems were not improved. Skeletal muscle coordination was slightly improved following improvement in the consciousness score, and the latter was improved 6 and 24 h after Normal, walks normally 0
Minimal ataxia, walks with some impairment of gait 4
Ataxia, but able to climb the wire net 6
Stands spontaneously, falls with a few steps 10
Sits, just able to circle 12
Posed lateral or dorsal recumbency 16
No movement 18 embolization in Group 2 and 24 h after embolization in Group 3 (Fig. 2) . In Group 3, behaviors such as aggression and escape were observed from 1 h after start of urokinase infusion. Furthermore, although these animals showed paralysis in the right hand and leg, one of them was able to climb the wire net. Although Group 3 consisted of 5 animals until 6 h after embolization, 2 of the 5 animals had died within 4 h following the end of urokinase infusion, and three animals remained until 24 h after embolization. However, the 2 animals that died in Group 3 had shown remarkable improvement in the consciousness category of the neurologic deficits score 6 h following embolization. The mean infarct size was 24.7 ± 3.5% of the hemisphere in Group 1, whereas those in Groups 2 and 3 were 11.9 ± 3.9% and 7.6 ± 2.5%, respectively. The infarct size was significantly smaller in the urokinasetreated groups (Group 2 and 3) as compared to Group 1 (Fig. 4, P<0.05) . Infarction involved mostly the caudate nucleus, putamen, globus pallidus, claustrum, and genu of the internal capsule, but not the insular cortex or area around the sulcus lateralis (Fig. 3) . The 2 animals that died in Group 3 showed cerebral edema and hemorrhage in the caudate nucleus. Furthermore, when animals treated with urokinase were sacrificed 24 h after embolization, the clot injected into the MCA was lysed partially or completely. In 2 animals that died, the clot was completely lysed.
Discussion
The purpose of this study was to evaluate the safety and efficacy of intra-arterial thrombolysis using urokinase in a primate thromboembolic stroke model. We demonstrated that intra-arterial urokinase improved neurologic deficits and the area of infarction induced by thromboembolic stroke in primates. We used a dose rate sufficient for the production of detectable fibrino- genolysis (120,000 IU / 6 h, Group 3) and intra-arterial infusion for long periods. In Group 3, animals showed a highly significant improvement in consciousness and skeletal muscle coordination categories of neurologic deficits. In addition to amelioration of the neurologic deficits score, urokinase significantly attenuated the ischemic area on the insula cortex and area around the sulcus lateralis. However, although urokinase protected neurologic function early after the start of infusion, a risk of urokinase was revealed. Specifically, 2 of the 5 animals died within 4 h after the end of urokinase infusion.
We previously introduced the thromboembolic stroke model in cynomolgus monkeys without craniotomy. The embolic model used in this study was developed to imitate embolic human stroke. Changes in physiological parameters and cerebral blood flow have been described in detail elsewhere (22) and can be summarized as follows: To reduce pain, animals were injected with clots under inhalation anesthesia, but this procedure was essentially carried out in a conscious state. Therefore, the physiological parameters were measured using a telemetry method in conscious, unanesthetized monkeys. Blood pressure, heart rate, and body temperature tended to slightly increase compared with pre-values. Furthermore, cerebral blood flow was measured using positron emission tomography (25) . Cerebral blood flow was reduced around the area of the left middle cerebral artery, and reduction of cerebral blood flow was maintained for 24 h after embolization (reduced to 12.6% -14.2%). After MCA occlusion, almost all animals displayed acute neurologic deficits consistent with ischemia of the tissue supplied by the left lateral striate arteries. The usual clinical deficits included severe contralateral hemiparesis and drowsiness.
The primary goal of thrombolysis in ischemic stroke subjects should be the rapid restoration of blood supply. Intra-arterial administration of urokinase helps to achieve a high concentration of thrombolytic drug in the affected vascular territory without an excessive systemic dose rate. Although there are some reports about urokinase-treatment for cerebral embolism (26, 27) , the toxicity of urokinase remains an open question. Incidentally, treatment with intracarotid infusion of urokinase (20,000 IU/ min for 60 min) in baboons with MCA occlusion has been reported (26) , and Del Zoppo et al. (26) described the improvement in functional score in baboons receiving intracarotid urokinase following the 3-h period of MCA occlusion. These imply a practical role for induced fibrinolysis. In humans, it is reported that local intra-arterial thrombolysis with urokinase (20,000 to 1,250,000 IU / 60 min) achieves a high recanalization rate correlating with a good outcome, especially within the first 4 h (2). Our results also point out that intra-arterial therapy with urokinase is effective in promoting reperfusion and inhibiting the development of focal ischemic injury, when infusion is initiated immediately after stroke onset.
In thrombolytics, t-PA functions similarly to urokinase (28) . Edema and hemorrhage are reported as toxicological changes resulting from t-PA administration, although there are therapeutic effects in cerebral embolism (2, 29 -31) . It is suggested that urokinase also exerts similar toxicity to t-PA, because severe edema and hemorrhage were observed in the infarct area of animals that died in this study. Specifically, we confirmed in the primate model that over dosing (prolonged infusion) of urokinase increased the risk of cerebral hemorrhage. Thus, thrombolysis can be doubleedged, depending on the dose level and treatment time after onset of stroke.
In conclusion, our results indicate that intra-arterial thrombolysis using low dose urokinase treatment may benefit ischemic stroke by improving neurologic functions, attenuating infarction size, and reducing the risk of cerebral hemorrhage if administrated within 1 h of onset. In the future, combined therapy with local intra-arterial urokinase thrombolysis and neuroprotective drugs should be investigated to assess safety and extend the therapeutic time window.
